New hires and promotions in the med-tech industry, including: Exthera, Heartbeam, Owlet, Virocell.
Read More
Brian brings a wealth of relevant experience to the company as it embarks on its next phase of growth, having spent the last four years as CFO of the Cell and Gene Therapy Catapult
CDMO ViroCell Biologics has announced the appointment of Brian Collins as Chief Financial Officer (CFO).
Read More
Brian’s appointment adds to an experienced leadership team that will drive ViroCell’s growth strategy to become a leading global specialist CDMO in cell and gene therapy
London, UK and New York, US, 26 July 2023 – ViroCell Biologics (“ViroCell” or the “Company”), a specialist Contract Development and Manufacturing Organisation (“CDMO”) in cell and gene therapy clinical trials, announces the appointment of Brian Collins as Chief Financial Officer (“CFO”).
Read More
ViroCell Biologics announces the appointment of John A. Dawson CBE as chairman of the board of directors, facilitating the company's aspiration to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials.
Key highlights:
John A. Dawson has been appointed as chairman of the board of directors for ViroCell.
The appointment validates the commercial opportunity for ViroCell and represents another milestone as the company builds towards becoming a global market leader in the viral vector clinical trial CDMO market.
In 2022 John was awarded a commander of the order of the British Empire (CBE) for services to U.K. life science by HM Queen Elizabeth II.
ViroCell Biologics (“ViroCell”) today announces the appointment of John A. Dawson CBE as Chairman of the Board of Directors (“Chairman”).
ViroCell aspires to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials. John’s appointment as Chairman further validates the commercial opportunity for ViroCell and represents another major milestone as we build towards becoming a global market leader in the viral vector clinical trial CDMO market.
Read More
ViroCell Biologics (“ViroCell”) today announces the appointment of John A. Dawson CBE as Chairman of the Board of Directors (“Chairman”).
ViroCell aspires to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials. John’s appointment as Chairman further validates the commercial opportunity for ViroCell and represents another major milestone as we build towardsbecoming a global market leader in the viral vector clinical trial CDMO market.
Read More
A number of pharma-adjacent tech firms and non-profits announced personnel news in the month of November. We’ve rounded up some highlights below… CDMO ViroCell has a new chief operating officer, Nick Maishman…
Read More
ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).
ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
Read More
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).
The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…
Read More
ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.
Read More